BFA
TTNP

BlackRock Fund Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

BlackRock Fund Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.4M Buy
167
+24
+17% +$404K ﹤0.01% 3130
2016
Q3 		$3.02M Buy
143
+7
+5% +$136K ﹤0.01% 3066
2016
Q2 		$2.69M Buy
136
+135
+13,500% +$2.88M ﹤0.01% 3116
2016
Q1 		$15K Hold
1
– – ﹤0.01% 3923
2015
Q4 		$11K Buy
+1
New +$16.3K ﹤0.01% 4010

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

BlackRock Fund Advisors's TTNP Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Titan Pharmaceuticals (TTNP) stake by 17% in Q4 2016, buying an estimated $404K and bringing the position to 167 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

BlackRock Fund Advisors first reported a position in TTNP in Q4 2015 and has held it in 5 quarters since. The position peaked at $3.02M in Q3 2016. 47 funds tracked by Wall St. Rank hold TTNP as of Q4 2016.

  • BlackRock Fund Advisors held 167 shares of Titan Pharmaceuticals worth $2.4M as of Q4 2016.
  • BlackRock Fund Advisors bought 24 Titan Pharmaceuticals shares in Q4 2016, an estimated $404K.
  • Titan Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3130 holding.
  • BlackRock Fund Advisors first reported a position in Titan Pharmaceuticals in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Fund Advisors's Titan Pharmaceuticals position peaked at $3.02M in Q3 2016.
  • 47 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.